Our recent webinar on using realistic covariates with new Trial Simulator to optimize meropenem dosing in renally-impaired children is available to view now.
See the new Trial Simulator v2.3 in action as Dr. Edward Nehus of Cincinnati Children’s Hospital and Dr. Mark Lovern, VP of Integrated Drug Development at Certara, evaluate target attainment of meropenem in various age groups and fluid overload in children receiving continuous renal replacement therapy (CRRT), reconstructing a previously published Trial Simulator model. Meropenem is often prescribed in children receiving CRRT, but fluid overload can be present in ill children, affecting drug disposition.
https://www.certara....aired-children/
